Literature DB >> 25101977

The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell.

Takahiro Shima1, Toshihiro Miyamoto2, Yoshikane Kikushige2, Junichiro Yuda3, Taro Tochigi3, Goichi Yoshimoto2, Koji Kato2, Katsuto Takenaka2, Hiromi Iwasaki3, Shinichi Mizuno2, Noriko Goto4, Koichi Akashi5.   

Abstract

The cellular properties of leukemia stem cells (LSCs) are achieved at least through Class I and Class II mutations that generate signals for enhanced proliferation and impaired differentiation, respectively. Here we show that in t(8;21) acute myelogenous leukemia (AML), hematopoietic stem cells (HSCs) transform into LSCs via definitively-ordered acquisition of Class II (AML1/ETO) and then Class I (c-KIT mutant) abnormalities. Six t(8;21) AML patients with c-KIT mutants maintaining > 3 years of complete remission were analyzed. At diagnosis, all single LSCs had both AML1/ETO and c-KIT mutations. However, in remission, 16 out of 1,728 CD34(+)CD38(-) HSCs and 89 out of 7,187 single HSC-derived myeloerythroid colonies from these patients had AML1/ETO, whose breakpoints were identical to those found in LSCs. These cells had wild-type c-KIT, which expressed AML1/ETO at a low level, and could differentiate into mature blood cells, suggesting that they may be the persistent preleukemic stem cells. Microarray analysis suggested that mutated c-KIT signaling provides LSCs with enhanced survival and proliferation. Thus, in t(8;21) AML, the acquisition of AML1/ETO is not sufficient, and the subsequent upregulation of AML1/ETO and the additional c-KIT mutant signaling are critical steps for transformation into LSCs.
Copyright © 2014 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25101977     DOI: 10.1016/j.exphem.2014.07.267

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  13 in total

1.  A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.

Authors:  Shan Lin; Anetta Ptasinska; Xiaoting Chen; Mahesh Shrestha; Salam A Assi; Paulynn S Chin; Maria R Imperato; B J Aronow; Jingsong Zhang; Matthew T Weirauch; Constanze Bonifer; James C Mulloy
Journal:  Blood       Date:  2017-07-14       Impact factor: 22.113

Review 2.  Pre-malignant lymphoid cells arise from hematopoietic stem/progenitor cells in chronic lymphocytic leukemia.

Authors:  Yoshikane Kikushige; Toshihiro Miyamoto
Journal:  Int J Hematol       Date:  2015-02-03       Impact factor: 2.490

3.  Standing at odds: mutated RAS and hematopoietic stem cells.

Authors:  Monica Nafria; Constanze Bonifer
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

Review 4.  Mouse models for core binding factor leukemia.

Authors:  D W L Chin; N Watanabe-Okochi; C Q Wang; V Tergaonkar; M Osato
Journal:  Leukemia       Date:  2015-07-13       Impact factor: 11.528

5.  Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.

Authors:  Toshihiro Miyamoto; Koji Nagafuji; Tomoaki Fujisaki; Naoyuki Uchida; Kosei Matsue; Hideho Henzan; Ryosuke Ogawa; Ken Takase; Takatoshi Aoki; Michihiro Hidaka; Takanori Teshima; Shuichi Taniguchi; Koichi Akashi; Mine Harada
Journal:  Int J Hematol       Date:  2017-12-14       Impact factor: 2.490

Review 6.  An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1.

Authors:  Sayer Al-Harbi; Mahmoud Aljurf; Mohamad Mohty; Fahad Almohareb; Syed Osman Ali Ahmed
Journal:  Blood Adv       Date:  2020-01-14

Review 7.  Is lineage decision-making restricted during tumoral reprograming of haematopoietic stem cells?

Authors:  Geoffrey Brown; Isidro Sanchez-Garcia
Journal:  Oncotarget       Date:  2015-12-22

Review 8.  Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia.

Authors:  Federico Mosna; Michele Gottardi
Journal:  Stem Cells Int       Date:  2016-01-13       Impact factor: 5.443

9.  Expression of RUNX1-ETO Rapidly Alters the Chromatin Landscape and Growth of Early Human Myeloid Precursor Cells.

Authors:  Monica Nafria; Peter Keane; Elizabeth S Ng; Edouard G Stanley; Andrew G Elefanty; Constanze Bonifer
Journal:  Cell Rep       Date:  2020-05-26       Impact factor: 9.423

10.  ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.

Authors:  Jean-Baptiste Micol; Alessandro Pastore; Daichi Inoue; Nicolas Duployez; Eunhee Kim; Stanley Chun-Wei Lee; Benjamin H Durham; Young Rock Chung; Hana Cho; Xiao Jing Zhang; Akihide Yoshimi; Andrei Krivtsov; Richard Koche; Eric Solary; Amit Sinha; Claude Preudhomme; Omar Abdel-Wahab
Journal:  Nat Commun       Date:  2017-05-18       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.